Amelioration of TMAO through probiotics and its potential role in atherosclerosis

Atherosclerosis is a major cause of mortalities and morbidities worldwide. It is associated with hyperlipidemia and inflammation, and become chronic by triggering metabolites in different metabolic pathways. Disturbance in the human gut microbiota is now considered a critical factor in the atheroscl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Applied microbiology and biotechnology Jg. 103; H. 23-24; S. 9217 - 9228
Hauptverfasser: Din, Ahmad Ud, Hassan, Adil, Zhu, Yuan, Yin, Tieying, Gregersen, Hans, Wang, Guixue
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2019
Springer
Springer Nature B.V
Schlagworte:
Animals
Arteriosclerosis
Atherosclerosis
Atherosclerosis - physiopathology
Atherosclerosis - prevention & control
biochemical pathways
Biomedical and Life Sciences
Biosynthesis
Biotechnology
Canada
Cardiovascular disease
Carnitine
Cholesterol
Choline
Diabetes
Diet
Flavin
flavin-containing monooxygenase
Health aspects
Heart failure
Humans
Hyperlipidemia
Immune system
Inflammation
Intestinal microflora
intestinal microorganisms
Lecithin
Life Sciences
Lipids
Metabolic disorders
Metabolic pathways
Metabolites
Metabolomics
Methylamines - antagonists & inhibitors
Methylamines - metabolism
Mice
Microbial Genetics and Genomics
Microbiology
Microbiomes
Microbiota
Microbiota (Symbiotic organisms)
Microorganisms
microRNA
MicroRNAs
Mini-Review
miRNA
Mortality
oxidation
Phosphatidylcholine
phosphatidylcholines
Prevention
Probiotics
Probiotics - therapeutic use
Risk factors
Trimethylamine
Trimethylamine-N-oxide
Type 2 diabetes
Canada
Gut microbiota
TMAO
Probiotics
TMA lyases
Atherosclerosis
ISSN:0175-7598, 1432-0614, 1432-0614
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Atherosclerosis is a major cause of mortalities and morbidities worldwide. It is associated with hyperlipidemia and inflammation, and become chronic by triggering metabolites in different metabolic pathways. Disturbance in the human gut microbiota is now considered a critical factor in the atherosclerosis. Trimethylamine-N-oxide (TMAO) attracts attention and is regarded as a vital contributor in the development of atherosclerosis. TMAO is generated from its dietary precursors choline, carnitine, and phosphatidylcholine by gut microbiota into an intermediate compound known as trimethylamine (TMA), which is then oxidized into TMAO by hepatic flavin monooxygenases. The present review focus on advances in TMAO preventing strategies through probiotics, including, modulation of gut microbiome, metabolomics profile, miRNA, or probiotic antagonistic abilities. Furthermore, possible recommendations based on relevant literature have been presented, which could be applied in probiotics and atherosclerosis-preventing strategies.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ISSN:0175-7598
1432-0614
1432-0614
DOI:10.1007/s00253-019-10142-4